Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Pan-RAS Inhibitor RMC-7977 Overcomes Oncogenic RAS Signaling and Exerts Antileukemic Effects in CMML/AML Cells

Tessa Seale, Brandy Perkins, Theodora Chatzilygeroudi, Soren Cole, Kareem Battah, Maximilian Stahl, Mark J. Levis, Alexander J. Ambinder, Sandra Misale, Theodoros Karantanos

Blood (2024) 144 (Supplement 1): 5784.

https://doi.org/10.1182/blood-2024-211218

Published: 2024

Journal Articles

Efficacy and Tolerability of Blinatumomab in Clinical Trial Ineligible Patients with CD19+ Leukemias

John Preston Claiborne, Daniel Li, B. Douglas Smith, Mark J. Levis, Ivana Gojo, Amy E. DeZern, Alexander J. Ambinder, Tania Jain, Gabrielle T. Prince, Lukasz P. Gondek, Theodoros Karantanos, Gabriel Ghiaur, William Brian Dalton, Jonathan Allen Webster

Blood (2024) 144 (Supplement 1): 5904.

https://doi.org/10.1182/blood-2024-207608

Published: 2024

Journal Articles

Acute Lymphoblastic Leukemia (ALL) Outcomes after Allogeneic Blood or Marrow Transplantation (alloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) in the Era of More Effective Pre-Transplant Therapy

Blood (2024) 144 (Supplement 1): 3551.

https://doi.org/10.1182/blood-2024-212141

Published: 2024

Journal Articles

A Retrospective Cohort Analysis of Minimal Residual Disease (MRD) across Therapy in FLT3 Acute Myeloid Leukemia (AML)

Arshia Arora, Hua-Ling Tsai, Venkata Preetam Sandeep Kaduluri, Mark J. Levis, Alexander J. Ambinder

Blood (2024) 144 (Supplement 1): 6171.

https://doi.org/10.1182/blood-2024-211081

Published: 2024

Journal Articles

Outcomes By Frailty in IC-Ineligible Newly Diagnosed AML - a Real-World Evidence Comparison By Treatment with Hypomethylating Agents + Ivosidenib or Venetoclax

B. Douglas Smith, Curtis A. Lachowiez, Alexander J. Ambinder, Gary Binder, Anne Angiolillo, Ravi Potluri, Eros Papademetriou, Thomas W. LeBlanc

Blood (2024) 144 (Supplement 1): 2855.

https://doi.org/10.1182/blood-2024-210603

Published: 2024

Journal Articles

The Use of Antifungal Prophylaxis Is Associated with Worse Outcomes in Patients with Newly Diagnosed AML Treated with Venetoclax/HMA: A Retrospective Analysis of Patients in the Flatiron Health Database

Alexander J. Ambinder, Mark J. Levis, Xin Wang, Keith W. Pratz, Andrew H Matthews

Blood (2024) 144 (Supplement 1): 2436.

https://doi.org/10.1182/blood-2024-207062

Published: 2024

Journal Articles

A Multi-Site Break through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib (Trial In Progress)

Blood (2024) 144 (Supplement 1): 4265.2.

https://doi.org/10.1182/blood-2024-201582

Published: 2024

Journal Articles

A Retrospective Analysis of Intensive Chemotherapy Vs. Venetoclax/Hypomethylating Agents for Patients Aged 60-75 with Favorable-Risk, NPM1-Mutated AML

Andrew Zale, Alexander J. Ambinder, Venkata Preetam Sandeep Kaduluri

Blood (2024) 144 (Supplement 1): 450.

https://doi.org/10.1182/blood-2024-210320

Published: 2024

Journal Articles

Real-World Analysis of CPX-351 Induction in Acute Myeloid Leukemia-Myelodysplasia Related (AML-MR): An Updated Analysis from the Marrow Consortium

Daniel T Peters, Deedra Nicolet, Yazan F Madanat, Jesus D Gonzalez-Lugo, Alexander J. Ambinder, Onyee Chan, Michael Jamie Hochman, Najla H. Al Ali, Victoria Klein, Krzysztof Mrózek, Tara L. Lin, Alice Mims, Charles Foucar, Joshua F Zeidner

Blood (2024) 144 (Supplement 1): 324.

https://doi.org/10.1182/blood-2024-193667

Published: 2024

Journal Articles

Prognostic Impact of Secondary Versus De Novo Ontogeny in Acute Myeloid Leukemia (AML) Is Predominantly Accounted for By the European Leukemianet (ELN) 2022 Risk Classification

Michael J. Hochman, Megan Othus, Robert P. Hasserjian, Alexander J. Ambinder, Andrew M. Brunner, Mary-Elizabeth M. Percival, Christopher S. Hourigan, Ronan Swords, Amy E. DeZern, Elihu H. Estey, Judith E. Karp

Blood (2022) 140 (Supplement 1): 1430–1432.

https://doi.org/10.1182/blood-2022-164739

Published: 2022

Journal Articles

Gemtuzumab Ozogamicin for Cytoreduction in Hyperleukocytosis

Matthew Scarlotta, Jonathan Webster, Matthew Newman, Cory Schulz, Kristin Stokvis, Alexander J. Ambinder, Tania Jain, William Brian Dalton, Lukasz P. Gondek, Gabrielle T. Prince, Gabriel Ghiaur, Christopher S. Hourigan, Amy E. DeZern, Ivana Gojo, Jonathan Allen Webster, Mark J. Levis

Blood (2022) 140 (Supplement 1): 11747–11748.

https://doi.org/10.1182/blood-2022-160300

Published: 2022

Journal Articles

Pre- and Post-Transplant Measurable Residual IDH Mutations Are Not Associated with Relapse in Patients with IDH-Mutated AML

Niveditha Ravindra, Laura W. Dillon, Gege Gui, Christopher S. Hourigan, Alexander J. Ambinder

Blood (2022) 140 (Supplement 1): 3391–3392.

https://doi.org/10.1182/blood-2022-167374

Published: 2022

Journal Articles

Post-Remission Outcomes in Patients with Acute Myeloid Leukemia (AML) Are Similar between Hypomethylating Agent/Venetoclax Therapy and Intensive Chemotherapy after Accounting for Measurable Residual Disease (MRD) Status

Michael J. Hochman, Alexander J. Ambinder, Lukasz P. Gondek, Amy E. DeZern

Blood (2022) 140 (Supplement 1): 3387–3388.

https://doi.org/10.1182/blood-2022-164757

Published: 2022

Journal Articles

Outcomes of Patients with TP53 -Mutated Myeloid Neoplasms (TP53-MN) and the Role of Allogenic Blood or Marrow Transplantation (alloBMT)

Sergiu Pasca, Saurav D. Haldar, Alexander J. Ambinder, Jonathan Webster, Tania Jain, William Brian Dalton, Gabrielle T. Prince, Gabriel Ghiaur, Amy E. DeZern, Ivana Gojo, Jonathan Allen Webster, Cory Schulz, Kristin Stokvis, Mark J. Levis, Richard J. Jones, Lukasz P. Gondek

Blood (2022) 140 (Supplement 1): 10629–10631.

https://doi.org/10.1182/blood-2022-169148

Published: 2022

Journal Articles

Allogeneic Blood or Marrow Transplantation (AlloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) for Acute Lymphoblastic Leukemia (ALL) in Patients Aged ≥ 55: Best Results in B ALL in First Remission (CR1) with Reduced-Intensity Conditioning (RIC)

Blood (2022) 140 (Supplement 1): 4813–4815.

https://doi.org/10.1182/blood-2022-171038

Published: 2022

Journal Articles

Response Prediction to Isocitrate Dehydrogenase (IDH) Inhibitors in Patients with IDH1 - or IDH2 -Mutated Acute Myeloid Leukemia Using Clinical and Genomic Data

Blood (2021) 138 (Supplement 1): 1285.

https://doi.org/10.1182/blood-2021-147099

Published: 2021

Journal Articles

Nonmyeloablative Allogeneic Transplantation in First Remission for Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Outcomes By Receipt of Pre-Transplant Blinatumomab

Blood (2021) 138 (Supplement 1): 1846.

https://doi.org/10.1182/blood-2021-153750

Published: 2021

Journal Articles

Incorporating Gemtuzumab into the Treatment of Core Binding Factor Acute Myeloid Leukemia: A Single Center Experience

Natalie S Rosen, Matthew L Smith, Amy E. DeZern, Alexander J. Ambinder

Blood (2021) 138 (Supplement 1): 2337.

https://doi.org/10.1182/blood-2021-144443

Published: 2021

Journal Articles

β-2-Glycoprotein Antibodies Activate the Alternative Pathway of Complement in Antiphospholipid Antibody Syndrome

Andrea C. Baines, MD PhD, Xuan Yuan, MD MSc, Eleni Gavriilaki, MD PhD, Alexander J. Ambinder, MD MPH, Alka Jain, PhD, Neal S. Fedarko, PhD, C. John Sperati, MD MHS, Alison R. Moliterno, MD, Rakhi P. Naik, MD MHS, Michael Streiff, MD, Wei Fu, MS, Michelle Petri, MD MPH, Robert A. Brodsky, MD

Blood (2016) 128 (22): 3818.

https://doi.org/10.1182/blood.V128.22.3818.3818

Published: 2016

Journal Articles

Modified Ham test for atypical hemolytic uremic syndrome

Eleni Gavriilaki, Xuan Yuan, Zhaohui Ye, Alexander J. Ambinder, Satish P. Shanbhag, Michael B. Streiff, Thomas S. Kickler, Alison R. Moliterno, C. John Sperati, Robert A. Brodsky

Blood (2015) 125 (23): 3637–3646.

https://doi.org/10.1182/blood-2015-02-629683

Published: 2015

Includes: Supplemental data

NARROW

Pan-RAS Inhibitor RMC-7977 Overcomes Oncogenic RAS Signaling and Exerts Antileukemic Effects in CMML/AML Cells

Efficacy and Tolerability of Blinatumomab in Clinical Trial Ineligible Patients with CD19+ Leukemias

Acute Lymphoblastic Leukemia (ALL) Outcomes after Allogeneic Blood or Marrow Transplantation (alloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) in the Era of More Effective Pre-Transplant Therapy

A Retrospective Cohort Analysis of Minimal Residual Disease (MRD) across Therapy in FLT3 Acute Myeloid Leukemia (AML)

Outcomes By Frailty in IC-Ineligible Newly Diagnosed AML - a Real-World Evidence Comparison By Treatment with Hypomethylating Agents + Ivosidenib or Venetoclax

The Use of Antifungal Prophylaxis Is Associated with Worse Outcomes in Patients with Newly Diagnosed AML Treated with Venetoclax/HMA: A Retrospective Analysis of Patients in the Flatiron Health Database

A Multi-Site Break through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib (Trial In Progress)

A Retrospective Analysis of Intensive Chemotherapy Vs. Venetoclax/Hypomethylating Agents for Patients Aged 60-75 with Favorable-Risk, NPM1-Mutated AML

Real-World Analysis of CPX-351 Induction in Acute Myeloid Leukemia-Myelodysplasia Related (AML-MR): An Updated Analysis from the Marrow Consortium

Prognostic Impact of Secondary Versus De Novo Ontogeny in Acute Myeloid Leukemia (AML) Is Predominantly Accounted for By the European Leukemianet (ELN) 2022 Risk Classification

Gemtuzumab Ozogamicin for Cytoreduction in Hyperleukocytosis

Pre- and Post-Transplant Measurable Residual IDH Mutations Are Not Associated with Relapse in Patients with IDH-Mutated AML

Post-Remission Outcomes in Patients with Acute Myeloid Leukemia (AML) Are Similar between Hypomethylating Agent/Venetoclax Therapy and Intensive Chemotherapy after Accounting for Measurable Residual Disease (MRD) Status

Outcomes of Patients with TP53 -Mutated Myeloid Neoplasms (TP53-MN) and the Role of Allogenic Blood or Marrow Transplantation (alloBMT)

Allogeneic Blood or Marrow Transplantation (AlloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) for Acute Lymphoblastic Leukemia (ALL) in Patients Aged ≥ 55: Best Results in B ALL in First Remission (CR1) with Reduced-Intensity Conditioning (RIC)

Response Prediction to Isocitrate Dehydrogenase (IDH) Inhibitors in Patients with IDH1 - or IDH2 -Mutated Acute Myeloid Leukemia Using Clinical and Genomic Data

Nonmyeloablative Allogeneic Transplantation in First Remission for Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Outcomes By Receipt of Pre-Transplant Blinatumomab

Incorporating Gemtuzumab into the Treatment of Core Binding Factor Acute Myeloid Leukemia: A Single Center Experience

β-2-Glycoprotein Antibodies Activate the Alternative Pathway of Complement in Antiphospholipid Antibody Syndrome

Modified Ham test for atypical hemolytic uremic syndrome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only